Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes

Details for Australian Patent Application No. 2006263332 (hide)

Owner Hadasit Medical Research Services & Development Ltd.

Inventors Niv, Masha; Reuveni, Hadas; Ziv, Ehud; Shafrir, Eleazar

Agent Freehills

Pub. Number AU-B-2006263332

PCT Pub. Number WO2007/000770

Priority 60/694,691 29.06.05 US

Filing date 28 June 2006

Wipo publication date 4 January 2007

Acceptance publication date 23 February 2012

International Classifications

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

A61K 38/00 (2006.01) Medicinal preparations containing peptides

C07K 7/00 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 7/06 (2006.01) Peptides having 5 to 20 amino acids in a fully defined sequence

C07K 14/81 (2006.01) Peptides having more than 20 amino acids - Protease inhibitors

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

Event Publications

24 January 2008 PCT application entered the National Phase

  PCT publication WO2007/000770 Priority application(s): WO2007/000770

23 February 2012 Application Accepted

  Published as AU-B-2006263332

21 June 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006263337-Modified release pharmaceutical compositions on the basis of two polymers and processes thereof

2006263331-Recombinant interferon alpha2 (IFNalpha2) mutants